About the Janssen Pharmaceutical Companies At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
Description: Elastomics AB is a biotechnology company specializing in the early-stage research and development of innovative medicines, focusing on the treatment of fibrotic diseases and other novel applications of matrix biology and biotechnology.
Cadila Pharmaceuticals Sweden AB is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the World.
Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, biotechnology products, plant tissue culture and more than 38 APIs and intermediates. In the services realm, our offering includes Pre-Clinical and Clinical Research as well as Contract Manufacturing.
We have scientific collaborations with leading Swedish companies for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.
The Swedish office has been set up to ensure success of ongoing and future collaborations between Swedish companies and institutions, and our Indian organization. We encourage regional researchers and companies to get in touch with us to discuss potential collaborations or our service offerings.
Description: QuiaPEG Pharmaceuticals AB, a privately held biotechnology company, offers pharmaceutical companies access to a new and enhanced proprietary PEGylation technology platform with significant advantages compared to its competitors improving therapeutic efficiency, cost-of-goods, safety and quality while facilitating life-cycle management.
QuiaPEG aims to become an esteemed partner on the growing market of biopharmaceuticals in general and the emerging market of biobetters in particular. This is achieved by licensing agreements providing access to the technology platform and collaboration agreements regarding QuiaPEGs proprietary biobetters. By building on the success of existing, approved biologics, the development of biobetters is considered much less of a commercial risk than developing a brand new class of biologics.
Despite the currently available drug treatment alternatives, a large group of patients with ulcerative colitis suffer from severe symptoms such as pain and frequent, bloody diarrhea. The only remaining option for many of these patients is to undergo colectomy.
InDex Pharmaceuticals develops Kappaproct – a completely new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based immunomodulatory sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
The European marketing rights for Kappaproct have been out-licensed to Almirall S.A. in an agreement that could potentially bring InDex milestones in excess of 100 million euro, as well as well as double-digit royalties.